Login to Your Account



200 Patients Added

Synta Raises $52M in Offering to Fund Ganetespib’s Phase III

By Randy Osborne
Staff Writer

Wednesday, November 13, 2013
Synta Pharmaceuticals Corp.’s new money from a public offering – about $52.5 million in gross proceeds – will fuel an expanded Phase III push with the heat-shock protein 90 inhibitor ganetespib in non-small-cell lung cancer (NSCLC).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription